This grant explores the hypothesis that methylation-directed inactivation of TSGs often implicated during early onset of disease exacerbates CRC progression, and that co-targeting dysregulated epigenetic regulators in CIMP-positive tumors will restore the critical function of TSGs and potentially lead to the development of chemoprevention. Furthermore, the methylation profiling offers an opportunity to improved stratification of CRC patients.
|Drug for colorectal cancer
|Effective start/end date
|15/08/17 → 14/08/19
- United States Department of Defense (DOD): A$315,413.00
Christine Findlay (Manager)Faculty of Medicine Nursing and Health Sciences Research Platforms
Andrew Fryga (Manager)Faculty of Medicine Nursing and Health Sciences Research Platforms
Trevor Wilson (Manager)Hudson Institute - Department of Molecular and Translational Science